VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has recently filed national applications at the U.S. Patent and Trademark Office designed to provide additional patent protection for its lead product candidate, PH94B. The company has also filed similar applications with counterpart patent authorities in major pharmaceutical markets outside the United States. The filings are related to PH94B and the treatment of adjustment disorder (“AjD”). According to the company, these filings are a strategic “next step” in VistaGen’s ongoing efforts to enhance potential commercial protection across its CNS pipeline in key pharmaceutical marketsand provide global exclusivity platform for PH94B in AjD; the company is working to provide patent protection that is similar to that of its protection for PH94B for the treatment of social anxiety disorder (“SAD”) as well as its exclusive late-clinical stage product candidate, PH10, for the treatment of major depressive disorder (“MDD”). The company also noted that it is in the process of finalizing an acquisition of its acquisition of Pherin Pharmaceuticals Inc., which will include Pherin’s entire pherine pipeline as well as intellectual property rights to PH94B, a substance that is in phase 3 development for the treatment of SAD and phase 2 development for the treatment of AjD with anxiety (“AjDA”), and PH10, which is in clinical development for MDD. The acquisition will also give VistaGen full ownership of three new early clinical-stage pherine product candidates: PH15 for cognition improvement, PH284 for appetite-related disorders, and PH80 for migraine and hot flashes.

To view the full press release, visit https://ibn.fm/OVJEk

About VistaGen Therapeutics Inc.

VistaGen is a late clinical-stage CNS-focused biopharmaceutical aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple types of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression — one mind at a time. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork